Galderma Group AG (SWX: GALD)
Health Care · Pharmaceuticals · CH
CHF164.95
+1.32% today · +12.1% 1Y
Galderma Group AG (SWX: GALD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $46.30B and employs 7,676 people.
Over the last twelve months the share price has gained 12.1%, trading between 134.70 and 188.25.
Tweenvest scores Galderma Group AG across four factors: quality 79/100, value 53/100, dividend 4/100. Its strongest factor is quality.
GALD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.30B
- Revenue (TTM)
- $5.92B
- P/E
- 55.89
- EPS
- 3.65
- Dividend yield
- 0.21%
- Beta (5Y)
- -0.05
- 52-week high
- CHF188.25
- 52-week low
- CHF134.70
- Avg volume (3M)
- —
- Shares outstanding
- 233.19M
- Employees
- 7,676
- Next earnings
- —
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
- ISIN
- CH1335392721
- Founded
- 1981
- Listed since
- Mar 22, 2024
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Chugai Pharmaceutical Co., Ltd.TSE: 4519 | $62.54B | ¥6,019.00 | -1.44% |
| Takeda Pharmaceutical Company LimitedTSE: 4502 | $58.92B | ¥5,843.00 | +0.46% |
| Bayer AktiengesellschaftXTRA: BAYN | $48.15B | €43.77 | +2.77% |
| Teva Pharmaceutical Industries LimitedNYSE: TEVA | $47.89B | $41.10 | +4.71% |
| Jiangsu Hengrui Pharmaceuticals Co.,LtdSHSE: 600276 | $46.07B | CN¥46.85 | -0.34% |
| Sun Pharmaceutical Industries LimitedNSEI: SUNPHARMA | $43.63B | Rs1,760.00 | +0.01% |
| UCB SAENXTBR: UCB | $43.44B | €203.50 | +0.84% |
| Haleon plcLSE: HLN | $40.71B | £3.49 | +1.42% |
Figures last refreshed Oct 11, 2026.